# Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis

> **NCT05486104** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ganzhou Hemay Pharmaceutical Co., Ltd** · enrollment: 92 (actual)

## Conditions studied

- Moderate to Severe Ulcerative Colitis

## Interventions

- **DRUG:** Hemay005 tablets
- **DRUG:** Hemay005 placebo tablets

## Key facts

- **NCT ID:** NCT05486104
- **Lead sponsor:** Ganzhou Hemay Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-08
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05486104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05486104, "Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05486104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*